Winston Francois builds retention programs that hold up to MLR review, respect HIPAA at the schema level, and keep HCP relationships intact when a payer changes the rules overnight. We embed as your fractional retention team, not a vendor who hands you a deck and disappears.
The Problem
Retention Marketing Gets Mistaken for a Medical Adherence Program
The moment a marketing team proposes a refill reminder or a persistence campaign, medical, legal, and regulatory read it as a clinical intervention and route it through the same review process built for labeling claims. That review cycle can run six to eight weeks for content that should take days. Marketing either stops proposing retention programs altogether or waters them down into generic reminders with none of the specificity that actually keeps a patient on therapy.
Hub Services and Marketing Run on Different Data, Different Vendors, Different Goals
Patient support programs and hub services are usually run by a third-party vendor under medical affairs or market access, and marketing has no system-level visibility into enrollment, refill status, or drop-off points. A patient can disenroll from the hub and marketing finds out a quarter later from a lagging report. Without a shared view, retention marketing is guessing at exactly the population it exists to serve.
The Line Between Reminder and Treatment-Decision Influence Is Not Written Down Anywhere
A refill reminder is fine. A message that nudges a patient toward staying on a specific dose, or frames a side effect in a way that discourages a call to their physician, crosses into territory that pulls FDA scrutiny and can trigger a warning letter. Most marketing teams do not have a documented, defensible line between the two, so every cadence gets built defensively, watered down until it barely moves persistence at all.
HCP Loyalty Programs Are Built for a Market That Does Not Flip Overnight
A specialty prescriber who has written your product for eighteen months can lose formulary access for their patient population in a single payer contract cycle, and every touchpoint built around clinical value and rep relationship becomes irrelevant to the actual decision driving prescribing. Loyalty programs modeled on consumer retention logic – reward the repeat behavior – collapse the moment the behavior stops being a choice the prescriber controls.
Consent and Opt-In Rules Differ by Stakeholder and Nobody Owns the Reconciliation
A patient consent captured through the hub, an HCP opt-in captured through a rep visit, and a caregiver contact captured through a support line all carry different legal bases for communication, and most CRM builds treat them as one contact record with one consent flag. When an audit asks who consented to what and when, the honest answer is often buried across three systems that were never designed to talk to each other.
Persistence Drops Hardest at the Exact Moment Nobody Is Watching
The highest-risk window for a patient going off therapy is usually the gap between hub enrollment and the first real engagement touch, or the weeks after a side effect call when the fastest thing a nurse educator can do is nothing. Without a lifecycle layer that actually triggers off those events, marketing finds out about the drop-off in a quarterly persistence report, long after the patient is gone.
How We Help
We start by drawing the line your organization has never written down: what counts as retention marketing and what counts as a medical adherence program subject to full MLR and regulatory review.
From there we map the actual patient and HCP journey across every system that touches it: the hub vendor's enrollment platform, the specialty pharmacy's fill data, the CRM your reps use, and whatever marketing automation exists today.
We build the cadence architecture next – refill reminders, nurse educator outreach windows, and re-engagement triggers – written to pass MLR review on the first pass because we scope the language and the trigger logic against the treatment-decision-influence line from day one.
On the data side, we build a consent and contact model that keeps patient consent, HCP opt-in, and caregiver contact as distinct, auditable records instead of one shared flag, so your legal team can answer a consent question in minutes instead of days.
For HCP retention, we build engagement models that separate clinical loyalty from access reality.
We measure persistence and re-enrollment the way your medical affairs team already measures clinical outcomes – with documented data lineage, not a marketing dashboard built from a different data source than the one compliance trusts.
We work embedded and fractional, sitting with your marketing, medical affairs, and hub vendor teams, not delivering a strategy deck and leaving the build to whoever inherits it next quarter.
What we deliver
- Documented boundary between retention marketing and medical adherence programs, scoped for MLR review
- Patient and HCP journey map across hub, specialty pharmacy, CRM, and marketing automation systems
- HIPAA-safe cadence architecture for refill reminders and nurse educator outreach with defensible trigger logic
- Consent and contact data model separating patient, HCP, and caregiver opt-in records
- Hub-to-CRM integration surfacing disenrollment and missed-refill triggers in real time
- HCP engagement model that weights formulary and payer access changes alongside clinical relationship signals
- Persistence and re-enrollment reporting with documented data lineage for compliance and board review
The reason most retention marketing programs in biotech and pharma stall is not the compliance review – it is that nobody ever wrote down where retention marketing ends and a medical adherence program begins, so every campaign gets built defensively from scratch.
Our Methodology
We run in 90-day sprints because that is enough time to get real infrastructure live without locking you into a plan built on assumptions that were already stale by day 30. Days 1-15 are the boundary-setting and audit phase: documenting the retention-versus-adherence line with your medical, legal, and regulatory stakeholders, and mapping where hub, CRM, and marketing automation data actually live today. Days 16-45 are the build: cadence architecture, consent data model, and the integration work connecting hub events to marketing triggers. Days 46-75 run the program against live patient and HCP populations, not a staging environment, so MLR feedback comes from real campaigns instead of hypotheticals. Days 76-90 are handoff and documentation, including the review-ready rationale packet that makes your next campaign faster to approve than this one.
This is different from a typical agency engagement in one specific way: we do not hand off a persistence strategy and let your team figure out the compliance conversation alone. We sit in the MLR review with you, defend the trigger logic we built, and stay on as the program runs so the person who answers a compliance question is the same person who built the cadence, not an account manager relaying it secondhand.
How We Work
The first 30 days are diagnostic and cross-functional. We sit with marketing, medical affairs, market access, and your hub vendor to map the real patient and HCP journey and document the retention-versus-adherence boundary before a single piece of content gets written.
Days 31-60 are build and integration. We are inside your CRM and marketing automation stack alongside your existing team, building the cadence logic, the consent model, and the hub data connection, with weekly working sessions instead of status calls that do not move the build forward.
By day 90 you have a live retention program with documented MLR-ready rationale, not a strategy memo waiting on a review calendar. From there we typically stay on as a fractional team – weekly during active campaign builds, biweekly once the program is stable and the focus shifts to HCP loyalty and formulary-responsive outreach.
If your biotech or pharma company needs retention marketing that survives an MLR review and a payer contract change in the same quarter, we should talk.
- Faster MLR review cycles for retention content with pre-documented rationale
- Reduced patient drop-off in the gap between hub enrollment and first engagement
- HCP outreach that adjusts to formulary and payer access changes instead of lagging behind them
- One auditable consent record per stakeholder type instead of a shared, ambiguous flag
- Persistence and re-enrollment reporting that holds up under compliance and board scrutiny
- Reduced dependency on hub vendor reporting lag for marketing decisions
If your biotech & pharma company needs retention marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How is retention marketing different from a patient adherence program that medical affairs already runs?
A medical adherence program is a clinical intervention designed and reviewed as part of patient care, usually run through the hub or a nurse educator line under medical affairs oversight. Retention marketing operates on the commercial side – refill logistics, insurance navigation, re-engagement outreach – and should never be positioned or written in a way that makes a treatment recommendation.
Can marketing send refill reminders without crossing into medical advice?
Yes, as long as the content sticks to logistics – insurance status, pharmacy pickup windows, appointment scheduling – and never frames dosage, side effects, or treatment continuation in a way that reads as clinical guidance. We write the trigger logic and message copy against a documented line so reviewers can approve it on the same basis every time instead of re-litigating the boundary with every submission.
How do you handle HIPAA when connecting hub data into a marketing CRM?
We treat patient-level data from the hub and general HCP engagement data as separate categories from the first day of the build, because they carry different legal bases for use and different consent requirements. The integration surfaces operational triggers – a missed refill, a disenrollment event – without pulling clinical detail into systems that were never built to hold protected health information.
What happens to our HCP loyalty program when a payer drops formulary coverage for our product?
A loyalty model that only tracks clinical relationship signals keeps rewarding a prescriber for behavior the payer has just made impossible, which wastes spend and reads as tone-deaf to the prescriber. We build formulary and payer access status into the engagement model as a first-class signal, so outreach shifts to access-navigation support the moment coverage changes instead of continuing a script built for a market that no longer exists.
Do you work with our existing hub services vendor or replace them?
We work with your existing hub vendor. Replacing an established patient support program is rarely the right call and is not what retention marketing is for.
How long does it take to get an MLR-ready retention program live?
Most engagements reach a live, reviewed cadence within the 90-day sprint, with the first 15 days spent documenting the retention-versus-adherence boundary alongside your medical, legal, and regulatory stakeholders. Programs that skip that documentation step tend to stall in review for months regardless of how good the campaign concept is, so we treat it as the highest-leverage work in the entire engagement.
What does a retention marketing engagement cost for a biotech or pharma company?
Engagements are scoped fractional, typically in the range of $15K-$35K per month depending on how many systems need to be connected and how much cross-functional review the cadence requires. That covers an embedded team working directly with your marketing, medical affairs, and hub vendor stakeholders, not a fixed deliverable list handed off after a single kickoff call.
